Paras Biopharmaceuticals Finland Oy

PB (MDT)-3010 (Biosimilar candidate to Novolog®)

• Paras Biopharmaceuticals Finland Oy has successfully developed a high expression and have Analog Insulin Biosimilar production clones.
• Rapid acting analog "Aspart" is produced with Paras Diabrid^™ Technology.
• The process for the production of insulin "Aspart" is currently being prepared for worldwide PCT patent submission. These technological innovations by Paras Biopharmaceuticals reduces the costs of industrial production of Insulin "Aspart" achieving higher economic advantages.

Novolog^® is a registered trademark of/marketed by Novo Nordisk.